FGFRs (®broblast growth factor receptors) are encoded by four genes (FGFR1 ± 4). Alternative splicing results in various receptor isoforms. The FGFR2-IIIb variant is present in a wide variety of epithelia, including the bladder epithelium. Recently, we have shown that FGFR2-IIIb is downregulated in a subset of transitional cell carcinomas of the bladder, and that this downregulation is associated with a poor prognosis. We investigated possible tumour suppressive properties of FGFR2-IIIb by transfecting two human bladder tumour cell lines, J82 and T24, which have no endogenous FGFR2-IIIb expression, with FGFR2-IIIb cDNA. No stable clones expressing FGFR2-IIIb were isolated with the J82 cell line. For the T24 cell line, stable transfectants expressing FGFR2-IIIb had reduced growth in vitro and formed fewer tumours in nude mice which, in addition, grew more slowly. The potential mechanisms leading to decreased FGFR2-IIIb mRNA levels were also investigated. The 5' region of the human FGFR2 gene was isolated and found to contain a CpG island which was partially methylated in more than half the cell lines and tumours which do not express FGFR2-IIIb. No homozygous deletion was identi®ed in any of the tumours or cell lines with reduced levels of FGFR2-IIIb. Mutational analysis of the entire coding region of FGFR2-IIIb at the transcript level was performed in 33 bladder tumours. In addition to normal FGFR2-IIIb mRNA, abnormal transcripts were detected in two tumour samples. These abnormal mRNAs resulted from exon skipping which aected the region encoding the kinase domain. Altogether, these results show that FGFR2-IIIb has tumour growth suppressive properties in bladder carcinomas and suggest possible mechanisms of FGFR2 gene inactivation.
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Introduction
Urothelial cell carcinoma is the fourth most common cancer in men and the ninth most common cancer in women in Western countries. Bladder carcinomas are either muscle-invasive or super®cial. Muscle-invasive tumours are associated with a high risk of metastases and a poor prognosis, despite radical therapy. Unpredictably, super®cial tumours may recur, and in 20% of cases they progress to muscle-invasive disease (Lamm and Torti, 1996) .
In the search for new markers of bladder tumour progression, we have previously reported that FGFR2-IIIb (®broblast growth factor receptor 2-IIIb) was expressed in the normal bladder urothelium and that its expression was decreased in a subset of bladder carcinomas, this change of expression being associated with a poor prognosis (Gil Diez de . There are four genes (FGFR1, FGFR2, FGFR3 and FGFR4) in mammals encoding FGF receptors (FGFRs) . FGFRs are glycoproteins consisting of two or three extracellular immunoglobulin (Ig)-like domains, an hydrophobic transmembrane region and a cytoplasmic part containing a tyrosine kinase catalytic site. Alternative mRNA splicing mechanisms produce various receptor isoforms (Johnson and Williams, 1993; McKeehan et al., 1998) . Isoforms FGFR2-IIIb and FGFR2-IIIc result from a mutually exclusive splicing event in which the second half of the juxtamembrane Ig-like domain of FGFR2 is encoded by either the 148-nucleotide IIIb exon or the 145-nucleotide IIIc exon (Miki et al., 1992) . FGFR2-IIIb is present exclusively in epithelial cells and binds the stromal cell-derived factor FGF7/KGF with high anity Rubin et al., 1989; OrrUrtreger et al., 1993; LaRochelle et al., 1995) .
Growth factors and their cognate receptors may positively or negatively regulate tumour progression (Sporn and Roberts, 1988; Cross and Dexter, 1991; Aaronson, 1991) . In many cases, FGFs and their receptors are thought to promote tumour progression. The upregulation of FGFs and FGFRs has been reported in many cancers: FGFR1 for astrocytomas (Yamaguchi et al., 1994) , FGF5, FGF7 and FGFR2-IIIb for pancreatic cancer (Kornmann et al., 1997; Ishiwata et al., 1998) , FGF2 for melanomas (Halaban et al., 1987 (Halaban et al., , 1988 Becker et al., 1989; Reed et al., 1994) , and FGF3 in MMTV-induced mouse mammary tumours (Muller et al., 1990; Shackleford et al., 1993) . Several in vitro and in vivo investigations have shown that FGF2 and FGFR1 are essential for melanoma growth (Wang and Becker, 1997; Yayon et al., 1997) . In haematopoietic malignancies, translocations involving FGFR1 or FGFR3 have demonstrated that FGF receptors may have oncogenic properties (Chesi et al., 1997; Xiao et al., 1998) . In direct contrast to their positive eects on cell growth, invasiveness, motility and angiogenesis, some data point to an inhibitory eect of FGFs and FGF receptors on the growth of several tumour cell lines (Schweigerer et al., 1987; Feng et al., 1997; Fenig et al., 1997; Johnson et al., 1998; Matsubara et al., 1998) . The mediation of inhibitory signals by FGF receptors is a developing concept in the ®eld of developmental biology. Germline mutations in humans and knockout experiments in mice have shown that FGFR3 negatively regulates bone growth (De Moerlooze and Dickson, 1997; Colvin et al., 1996; Deng et al., 1996) . There are very few reports suggesting that FGFs and FGFRs have an inhibitory role in human cancer that is lost as the tumour progresses. The loss of FGFR2-IIIc is closely associated with malignant progression in astrocytederived tumours (Yamaguchi et al., 1994) . Recently, we have shown that reduced expression of FGFR2-IIIb is associated with a poor prognosis in transitional cell carcinomas of the bladder (Gil Diez de Medina et al., 1997). We investigated whether FGFR2-IIIb has inhibitory properties in bladder cancers by a series of experiments to determine the eects of FGFR2-IIIb expression in human bladder tumour-derived cell lines lacking endogenous FGFR2-IIIb. We found that FGFR2-IIIb reduced cell proliferation in vitro and tumour formation in nude mice. We also investigated the possible genetic and epigenetic mechanisms of FGFR2 gene inactivation.
Results

Expression of FGFR2-IIIb in bladder tumour cell lines
The signi®cantly reduced level of FGFR2-IIIb in a subset of bladder tumours with poor prognosis (Gil Diez de Medina et al., 1997) led us to examine its expression in bladder tumour cell lines. Very little or no FGFR2-IIIb mRNA was detected in nine of 17 cell lines (53%). Seven cell lines expressed FGFR2-IIIb mRNA at similar levels to that of normal urothelium (Table 1) . None of the 17 cell lines did express FGFR2-IIIc, the other major splice variant of the FGFR2 gene (data not shown). Therefore, as observed in vivo (Gil Diez de , the decrease in FGFR2-IIIb mRNA was not associated with an increase in FGFR2-IIIc mRNA in vitro. In every sample in which protein and mRNA were both studied, there was agreement between the levels of mRNA and protein.
Expression of FGFR2-IIIb in transfected clones
We assessed the eect of FGFR2-IIIb on the malignant phenotype, by transfecting the J82 and T24 cell lines, which lack endogenous FGFR2-IIIb expression, with a mammalian expression vector containing the full-length human FGFR2-IIIb cDNA under the control of the cytomegalovirus (CMV) promoter (pcDNAI/Neo-FGFR2-IIIb, see Materials and methods). The vector without an insert was used as a control (pcDNAI/ Neo). J82 cells were selected by growth for 2 weeks on G418. Transfection with pcDNAI/Neo-FGFR2-IIIb gave almost half as many colonies as the vector alone ( Table 2) . None of the 13 FGFR2-IIIb-transfected clones tested expressed the FGFR2-IIIb mRNA, as detected by RT ± PCR analysis. Eleven of the 13 clones were tested for the presence of the transfected FGFR2-IIIb cDNA by genomic PCR analysis. The FGFR2-IIIb cDNA was not ampli®ed from any of these clones whereas the neomycin resistance gene was detected in all cases, indicating that the transfected clones selectively lost the FGFR2-IIIb transfected cDNA but retained a functional neomycin resistance gene. Thus, FGFR2-IIIb expression seems to be incompatible with the growth of J82 cells.
For T24 cells, transfection with the FGFR2-IIIbexpressing plasmid gave slightly, but not signi®cantly, more G418 resistant clones than did transfection with the control vector ( Table 2 ). In six of the ten FGFR2-IIIb-transfected clones tested the receptor was detected by semi-quantitative RT ± PCR (data not shown). The stable FGFR2-IIIb-expressing cells were similar in morphology to vector-alone controls and untransfected parental cells (data not shown). Protein levels were investigated by immunoblot analysis in three clones expressing FGFR2-IIIb mRNA (T24K4, T24K6, T24K10), in two control clones (T24N2, T24N4), in the parental cell line (T24) and in normal urothelium. The polyclonal anti-FGFR2 antibody recognized a 94 kD species corresponding to FGFR2-IIIb ( Figure 1a ). For two of the three transfected clones expressing FGFR2-IIIb, the amount of FGFR2-IIIb protein was similar to that of normal urothelium, whereas for the third, signi®cantly more FGFR2-IIIb protein was present. As expected, the FGFR2 protein was not detected in vector control samples or the parental cell line. We determined the subcellular Protein level determined by Western blot analysis; +, present; 7, absent; nd, not determined location of the FGFR2-IIIb protein by confocal immuno¯uorescence microscopy of the T24K10-transfected clone using the polyclonal anti-FGFR2 antibody. The FGFR2-IIIb protein was present at the cell surface, with some staining of cytoplasmic vesicular structures also apparent (Figure 1b) . We assessed the functionality of the transfected receptor, by determining FGFR2-IIIb phosphorylation status in T24K10 cells with or without KGF/FGF7 stimulation. Immunoblot analysis with anti-phosphotyrosine antibody showed that KGF strongly stimulated FGFR2-IIIb tyrosine phosphorylation. Little or no phosphorylation was observed in the absence of ligand (Figure 2 ).
Phenotype of stable FGFR2-IIIb-transfected clones T24K4, T24K6 and T24K10 clones were used to investigate the eects of FGFR2-IIIb on cell proliferation in vitro and tumour formation in nude mice.
The eects of FGFR2-IIIb on cell proliferation were assessed by assaying 3 H-thymidine incorporation. There was signi®cantly less thymidine incorporation in the FGFR2-IIIb expressing clones than in the parental cell line and the clones transfected with the vector only (T24N2, T24N4) ( Figure 3 ). The largest eect (90% less) was observed with the high expresser clone (T24K10). No further decrease in thymidine incorporation was observed if one of two FGFR2-IIIb ligands, FGF1 and FGF7, was added to the medium (data not shown).
We assessed the eects of FGFR2-IIIb expression on the growth of tumours in vivo, by injecting the FGFR2-IIIb expressing clones (T24K6, T24K10) and control clones (T24N2, T24N4) subcutaneously into the¯anks of female athymic nude mice. Mice injected with cells that did not express FGFR2-IIIb formed tumours within 5 weeks and mean tumour size was about 400 mm 3 after 20 weeks. Both the FGFR2-IIIbtransfected cell lines, T24K6 and T24K10, caused signi®cantly less tumour formation than the vectoronly controls (T24N2 and T24N4) (Figure 4 ). The number of tumours produced from the FGFR2-IIIbexpressing clones, T24K6 and T24K10, was noticeably smaller (17 and 0% respectively) than the number produced from the control group T24N2, and T24N4 (50 and 83% respectively) ( Table 3 ). In addition, the two tumours resulting from injection with the FGFR2-IIIb-transfected clones grew much more slowly than those arising from the control vector transfectants, reaching a maximum size of 40 mm 3 after 21 weeks, whereas control vector transfectants grew to a mean size of 500 mm 3 in the same time. The two small tumours produced by injection with the T24K6 clone were examined histologically, but there was no obvious dierence between these tumours and those obtained with the T24N2 and T24N4 control clones (data not shown). (Table 1 ) may be due to homozygous deletion of the FGFR2 gene. We therefore used duplex PCR to study a series of seven bladder carcinoma cell lines lacking FGFR2-IIIb and 25 primary bladder tumours including ten with low levels of FGFR2-IIIb. None of the cell lines or tumour samples investigated showed evidence of homozygous FGFR2 gene deletion.
CpG island methylation analysis of the FGFR2 gene in bladder tumour cell lines and primary bladder carcinomas Hypermethylation of normally unmethylated CpG islands in the promoter regions of genes correlates with loss of transcription. The proximal promoter region of the mouse FGFR2 gene has been characterized and found to contain a CpG island (Avivi et al., 1992) . A 181 bp probe from the 5' end of the human FGFR2 cDNA (+172 to +353, based on Figure 5 numbering) was used to isolate a human genomic PAC clone. We sequenced 1 kb upstream from the known 5' end of the cDNA (Hattori et al., 1990; Dell and Williams., 1992) . Sequences homologous to those of the mouse promoter were identi®ed and are shown in Figure 5a . The 5' end of the human FGFR2 gene (7352 to 441) has a G+C content of 75% and a CpG/ GpC ratio of 0.96, and is therefore a CpG island. A methylation-sensitive restriction map of *1000 bp extending from the promoter region through exon 1 of the FGFR2 gene is shown in Figure 5b . A PCRbased assay was used to analyse the methylation status of this CpG island. Double digestion using a restriction enzyme with¯anking cut (AfIII) and methylationsensitive enzymes (SmaI, HpaII or EagI) was followed by PCR ampli®cation of region 1 or 2. Normal urothelium is unmethylated at the sites tested within these two regions ( Figure 6 and data not shown). All cell lines (n=9) and primary tumours (n=6) expressing FGFR2-IIIb tested also had DNA that was unmethylated in these regions. In contrast, ®ve of the nine cell lines and ®ve of the nine primary bladder tumours that did not express FGFR2-IIIb were partially methylated ( Figure 6 and data not shown). These dierences in methylation were con®rmed by Southern blotting of DNA isolated from bladder tumour cell lines (data not shown). The treatment of cell lines with 5-aza-2'-deoxycytidine did not reactivate the expression of FGFR2 gene, as assessed by RT ± PCR for cell lines in which the CpG island was methylated, whereas this treatment clearly reactivated p16 expression in the T24 cell line (data not shown).
Loss of heterozygosity of the FGFR2 locus in human bladder cancer
The FGFR2 gene has been mapped to chromosome region 10q25.3-10q26 (Mattei et al., 1991) . Allelic loss on chromosome 10q occurs in about 50% of invasive bladder cancers (Cappellen et al., 1997) . We used two recently identi®ed microsatellites from the FGFR2 gene (Cappellen et al., submitted) to investigate the loss of heterozygosity (LOH) at the FGFR2 locus in 35 3 H-thymidine incorporation, measured as described in`Materials and methods', was assessed for the T24 parental cell line, two clones transfected with vector alone (T24 N2 and T24 N4), and three clones transfected with FGFR2-IIIb cDNA (T24 K4, T24 K6 and T24 K10). The amount of FGFR2-IIIb in these clones is shown in Figure 1 . Columns, mean values for quadruplicate wells; bars, s.d. , 1997) . LOH occurred in nine of 33 informative tumours. There was a decreased expression of FGFR2-IIIb in nine of these 33 tumours with no statistical correlation between these two factors (P=1.0, Fisher's exact test).
Screening for FGFR2-IIIb cDNA alterations in human bladder cancer
The entire coding region of FGFR2-IIIb was analysed at the transcript level by SSCP in two tumour bladder cell lines (SCaBER and 647V), 33 primary bladder cancer, one peritumoural urothelium and three normal urothelia. We detected aberrant SSCP patterns for three of the 39 cDNAs examined, the SCaBER cell line and two tumours (1512-6 and 1528-7). Sequencing of the DNA corresponding to the aberrant SSCP bands derived from SCaBER showed that there had been a Tto-C substitution, resulting in an amino acid change from Met to Thr at codon 186 (Miki et al., 1992) in the extracellular domain of FGFR2-IIIb. No corresponding normal tissue is available for this cell line, so we cannot exclude the possibility that this nucleotide variation is a polymorphism. Functional analysis is The variant allele was the only allele detected in the SCaBER cell line and it was not detected among the other 38 cDNAs tested (data not shown). We carried out DNA sequencing for the SSCP shifts in tumours 1512-6 and 1528-7 and found that the mRNA species were aberrant, due to the deletion of a single exon, exon 13 for 1512-6 and 17 for 1528-7. These two deletions aected the kinase domain of FGFR2-IIIb. The deletion in tumour 1512-6 removed 111 bp, resulting in a truncated protein lacking part of the kinase domain and the C-terminal end. The aberrant transcript in tumour 1528-7 had a 138 bp in-frame deletion. Both the aberrant and the wild-type mRNAs were present in these two tumours. We found that 2 ± 10% of the mRNA present was aberrant. Abnormal transcripts were not detected in any of the normal and peritumoral urothelia tested, including the peritumoral urothelium from patient 1528-7.
Discussion
FGFR2-IIIb has growth suppressive properties in human bladder carcinomas
Cancer development is a multistage process that results from the accumulation of genetic and epigenetic changes. From an ongoing interest in candidate genes whose expression is altered during the course of bladder carcinogenesis, we have recently found that the level of a particular isoform of the ®broblast growth factor receptor 2, FGFR2-IIIb, is decreased in a subset of bladder tumours, and that this downregulation is associated with a poor prognosis (Gil (Green et al., 1996) . The fact that little or no phosphorylation was observed in the absence of ligand does not support the ®rst hypothesis.
Mechanisms of FGFR2 gene inactivation
The inhibitory properties of FGFR2-IIIb and the frequent loss of or decrease in FGFR2-IIIb expression that occurs in about 30% of primary bladder tumours (Gil Diez de Medina et al., 1997) and 50% of cell lines, suggest that the inactivation of FGFR2-IIIb is a critical step in the development or progression of bladder cancer. Several mechanisms may be responsible for FGFR2 gene silencing. We detected no homozygous deletions in the cell lines and primary tumours analysed. We investigated the abnormal methylation of the 5' CpG island of the FGFR2 gene as a potential inactivation mechanism for this gene.
De novo methylation of the 5' CpG island of FGFR2 was observed in 50% of tumours and cell lines with little or no FGFR2-IIIb expression, whereas the CpG island was not methylated in FGFR2-IIIb expressing samples. Treatment of cell lines in which the 5' CpG island of FGFR2 was methylated with the demethylating agent 5-aza-2'-deoxycytidine did not restore FGFR2-IIIb expression (data not shown). Therefore, it is unclear whether FGFR2 methylation is the cause or consequence of FGFR2-IIIb downregulation. We are currently exploring other mechanisms of FGFR2 downregulation, such as the loss of a transactivator of the FGFR2 gene or altered chromatin structure in the FGFR2 region. Allelic loss on chromosome 10q, where FGFR2 is located, frequently occurs in bladder cancer (Cappellen et al., 1997) . We therefore looked for somatic mutations of FGFR2-IIIb. The entire coding region of FGFR2-IIIb was analysed at the transcript level in our bladder tumour samples by SSCP analysis. Distinct banding patterns were observed with two of 33 tumours (6%). These abnormal bands were tumour-speci®c and corresponded to transcripts lacking one exon (exon 13 or 17) encoding part of the kinase domain of FGFR2. We do not know whether this was due to aberrant alternative splicing or to a mutation resulting in exon skipping. Similar aberrant transcripts have been reported for the mdm 2 gene (Sigalas et al., 1996) and the potential tumour suppressor gene, FHIT (Ohta et al., 1996) . The role of these aberrant transcripts in tumour progression is still a matter of debate (Mao, 1998) . The two aberrant FGFR2 transcripts encode FGFR2-IIIb without a functional tyrosine kinase, which would act as dominant negative FGF receptors. The small proportion of aberrant transcripts in the tumours (less than 10%) leaves open the possibility that this is of real importance. It would be of value to determine whether a small proportion of the neoplastic cells express preferentially the aberrant transcripts, or whether all neoplastic cells express the aberrant transcripts, but at a low level. Tumour microdissection and cell line derivation should make it possible to determine which of these alternatives applies.
Mechanisms of FGFR2-IIIb-mediated growth inhibition
The mechanisms underlying the inhibitory properties of FGFR2-IIIb are unknown. FGFR1 is not present in the normal urothelium, but is expressed in many bladder carcinoma and cell lines, including T24 and J82 (data not shown), suggesting that FGFR1 may accelerate tumour progression. In transfected cells, FGFR2-IIIb may heterodimerise with FGFR1, inhibiting the signal transduced by FGFR1, as suggested by Feng et al. (1997) . Alternatively, FGFR2-IIIb may itself mediate an inhibition signal. Some FGF receptors induce the expression of the cell cycle inhibitor, p21/WAF1 (Su et al., 1997; Johnson et al., 1998) . This was not the case for FGFR2-IIIb in T24 cells because there was no more p21/WAF1 in the FGFR2-IIIb expressing T24 clones than in the control clones (data not shown).
Role of FGFR2-IIIb in other carcinomas
FGFR2-IIIb is expressed in various human epithelia and is not expressed in many carcinoma-derived cell lines (LaRochelle et al., 1995; Rubin et al., 1995; Carstens et al., 1997) . This suggests that the downregulation of FGFR2-IIIb in human carcinoma is not restricted to the bladder. In a rat tumour model, loss of FGFR2-IIIb expression is associated with malignant progression (Yan et al., 1993) . Furthermore, in this model, it has been recently shown that FGFR2-IIIb inhibits the growth of malignant cells both in vitro and in vivo (Feng et al., 1997 , Matsubara et al., 1998 . In human prostate tumour cell lines, Carstens et al. (1997) found that the loss of FGFR2-IIIb expression correlated with androgen insensitivity. It is unknown whether FGFR2-IIIb is downregulated in human prostate cancer samples. Unlike other carcinoma cell lines, many stomach carcinoma cell lines express FGFR2-IIIb, suggesting that, in these cancers, FGFR2-IIIb may accelerate tumour progression. Stomach carcinomas are the only tumours known in which a shorter form of FGFR2-IIIb is expressed, this shorter form being more oncogenic than the other forms of FGFR2-IIIb in a 3T3 transformation assay (Itoh et al., 1994) .
Conclusions
The downregulation of FGFR2-IIIb in a subset of bladder carcinomas with poor prognosis led us to investigate the inhibitory properties of this receptor and the potential mechanisms of FGFR2 gene inactivation. FGFR2-IIIb inhibits cell growth both in vitro and in vivo in bladder carcinomas. The FGFR2 gene is methylated in a signi®cant proportion of primary tumours and cell lines not expressing this gene. However FGFR2-IIIb cannot be de®ned as a true suppressor gene because no clear inactivating mutations have been identi®ed (Haber and Harlow, 1997) . In bladder carcinomas, FGFR2-IIIb behaves like E-cadherin, which is functionally a tumour suppressor gene, and the promoter of which is sometimes methylated, but which has a low frequency of mutation (Giroldi et al., 1994) . The levels of Ecadherin and FGFR2-IIIb are related: tumours with low levels of E-cadherin always have a low level of FGFR2-IIIb, suggesting a common mechanism of inactivation for these two genes (Gil Diez de Medina et al., 1999). There are probably two classes of negative regulators of tumor progression, those that are functionally and genetically tumour suppressor genes and those that meet only the functional criteria. A tumour suppressor gene satisfying the functional criteria in a given tumour (for example, E-cadherin in bladder carcinoma) may meet both the genetic and functional criteria in other types of tumour (E-cadherin in lobular breast carcinoma and in gastric carcinoma) (Guilford et al., 1998) . Further work is required to determine whether this is also the case for FGFR2.
Materials and methods
Tissue specimens
Normal urothelium (n=45) and transitional cell carcinomas of the bladder (n=33) were obtained as described elsewhere . Tumour samples contained more than 80% malignant cells, as determined by histological analysis of adjacent sections.
Cell culture, constructs and transfection
Human bladder cell lines T24, J82, TCCSUP and SCaBER were obtained from the ATCC (Rockville, MD, USA), EJ138 and RT112 from the ECACC (Salisbury, UK). 647V, SD48 and JON53 were provided by Professor D Chopin (HoÃ pital Henri Mondor, CreÂ teil, France). All cell lines were cultured in DMEM/F12+ (Dulbecco's Modi®ed Eagle Medium/F12 containing 10% heat-inactivated foetal calf serum, 2 mM glutamine, 100 units/ml penicillin, 100 mg/ml streptomycin, 10 mM HEPES, 50 nM hydrocortisone, 5 mg/ml apotransferrin and 5 nM selenium). For demethylation analysis, 5-aza-2'-deoxycytidine (Sigma) was added to the medium at concentrations of 0.3, 1 or 3 mM and cells were harvested after 3, 5 or 10 days of treatment. Lysates in 4 M guanidinium thiocyanate of the bladder cell lines HCV-29, HT-1376, RT4, VM-CUB-1, VM-CUB-3, 253-J, KK47, UM-UC3 were kindly provided by Dr J Southgate (Leeds, UK). The FGFR2-IIIb isoform used for transfection was KsamIIC1 (Itoh et al. 1994) , the principal isoform in normal urothelium and bladder carcinomas (D Cappellen, unpublished results) . The FGFR2-IIIb cDNA, in a cytomegalovirus promoter-driven pcDNAI/Neo expression vector (Invitrogen, San Diego, CA, USA) was provided by Drs M Terada and T Yoshida (National Cancer Centre Research Institute, Tokyo, Japan) (Itoh et al. 1994 ). This plasmid is called pcDNAI/ Neo-FGFR2-IIIb, and the control plasmid, pcDNAI/Neo. T24 and J82 cells (2610 5 /35 mm tissue culture plate) were transfected by a liposome-mediated method using LipofectA-MINE (Life Technologies). Three days after transfection, cells were transferred to 100 mm dishes ®lled with DMEM/ F12+ containing Geneticin (G418; Life Technologies), 400 mg/ml for T24 and 700 mg/ml for J82. Cell colonies on the selection medium were stained using Di-Quik staining solutions (Dade, Paris, France) and counted, or isolated and assessed for expression of FGFR2-IIIb.
Reverse transcription-PCR analysis
Total RNA was extracted using Trizol (Life Technologies) or caesium chloride centrifugation and used as the template for ®rst stand cDNA synthesis by random priming as previously described (Kandel et al. 1991 , Radvanyi et al. 1993 . The amount of FGFR2-IIIb mRNA was determined by semiquantitative radioactive RT ± PCR, using TBP (TATAbinding protein) as an internal control, as previously described . The number of cycles was selected so as to be in the exponential part of the PCR reactions (25 cycles). The PCR-ampli®ed products were subjected to electrophoresis in 8% polyacrylamide gels. Signals were quanti®ed with a Molecular Dynamics 300 PhosphorImager (Molecular Dynamics, Sunnyvale, CA, USA). There was no ampli®cation if reverse transcriptase was omitted from the reverse transcription reaction.
Immunodetection of FGFR2-IIIb
For Western blot analysis, cells were harvested at 80% con¯uence and lysed in 50 mM Tris-HCl (pH 7.4), 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM Na 3 VO 4 , 50 mM NaF, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 5 mM Pefabloc (Boehringer Mannheim, Meylan, France). Protein concentration was determined using the BioRad kit (BioRad, Ivry sur Seine, France). Protein (50 mg) of each extract was resolved by 10% sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS ± PAGE), transferred to nitrocellulose membrane (Schleicher and Schuell, Dassel, Germany) , and incubated with a rabbit polyclonal anti-FGFR2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Bound antibodies were detected with an anti-rabbit horse-radish peroxidaseconjugated secondary antibody (Amersham, Les Ulis, France), by enhanced chemiluminescence (ECL kit; Amersham).
For immuno¯uorescence analysis, cells were plated on coverslips in 24-well plates at a density of 2610 5 cells/well in DMEM/F12+. They were allowed to attach for 48 h, ®xed in cold methanol/acetone (1/1), and then incubated for 1 h at 378C with a rabbit polyclonal anti-FGFR2 antibody (Santa Cruz). The cells were washed with 0.2% gelatin in phosphate buered saline (PBS-gelatin) and incubated with biotinconjugated donkey anti-rabbit secondary antibody (Amersham) for 1 h at room temperature. The coverslips were washed and incubated for 45 min with Streptavidin-FITC (Amersham). The cells were washed, covered with mounting solution and examined with a Leica confocal microscope.
Tyrosine phosphorylation of FGFR2-IIIb
The T24 cell stable transfectants grown in the presence of G418 were washed once in PBS and incubated overnight at 378C in serum-free DMEM/F12. Cells were left unstimulated or were stimulated by incubation with 50 ng/ml KGF/FGF7 for 20 min. Cells were lysed as described above. Lysates (1 mg) were immunoprecipitated with rabbit polyclonal antibody PK1-2, raised against a synthetic oligopeptide corresponding to the 16 amino acids immediately downstream from the signal peptide in the extracellular region of FGFR2 (anti-FGFR2, 1 : 50 dilution) . Immunocomplexes were collected by incubation with antirabbit IgG-agarose (Sigma). Immunoprecipitated proteins were resolved by SDS ± PAGE (10%) and immunoblotted with the mouse anti-phosphotyrosine monoclonal antibody 4G10 (1.5 mg/ml). Bound antibody was detected with an antimouse horse-radish peroxidase-conjugated secondary antibody (Amersham), by enhanced chemiluminescence (ECL kit, Amersham). , ®xed in cold 10% trichloracetic acid, and washed twice with water. The cells were then dried, and were lysed in 0.1 M sodium hydroxide. Incorporated thymidine was determined using a scintillation counter.
Tritiated thymidine incorporation
Tumour formation in nude mice
Six-to 8-week-old female Swiss nu/nu mice weighing 20 to 25 g, bred in the animal facilities of the Curie Institute, Paris, France, were used for the assays. They were kept in speci®ed pathogen-free conditions. Their care and housing were in accordance with the institutional guidelines of the French Ethical Committee (MinisteÁre de l'Agriculture et de la ForeÃt, Direction de la SanteÂ et de la Protection Animale, Paris, France) and were supervised by authorized investigators. Cells were suspended in DMEM/F12 at a concentration of 5.10 7 cells/ml. Each nude mouse was injected subcutaneously twice in the dorsal¯ank region (0.2 ml; 10 7 cells/site). Cells from each clone were injected into six mice at two sites (12 injections for each cell population). Tumour formation was monitored for up to 21 weeks. Tumours were measured with Vernier calipers, and two perpendicular diameters were used to estimate tumour volume by the formula ab 2 /2, where a is the larger and b the smaller diameter. The animals were sacri®ced after 21 weeks. Half the tumours were frozen at 7808C for RNA extraction, and the other half were used for histological examination.
Loss of heterozygosity and homozygous deletion analysis of the FGFR2 gene Genomic DNA from cell lines, normal tissue and the corresponding tumour from the patient were prepared as previously described (Cappellen et al., 1997) . The FGFR2 gene contains two informative microsatellites (Cappellen et al., submitted) . Loss of heterozygosity (LOH) at the FGFR2 locus was determined as described, using these two markers (Cappellen et al., 1997) . Homozygous deletions were identi®ed by a PCR assay. A fragment containing exon 8 of the FGFR2 gene was coampli®ed with a genomic fragment of either GAPDH or PSA as control. The GAPDH and PSA genes map to chromosomal regions that are infrequently aected by allelic loss in bladder carcinomas. A 202 bp FGFR2 fragment (FGFR2-F1/ FGFR2-R1) was coampli®ed with a 136 bp GAPDH fragment. A 344 bp FGFR2 fragment (FGFR2-F2/FGFR2-R1) was coampli®ed with a 255 bp PSA fragment (PSA-F/ PSA-R). The primers used were asfollows: FGFR2-F1: 5'-AGAAGTGCTGGCTCTGTTCA-3'; FGFR2-R1: 5'-TCTC-CCAAAGCACCAAGTCT-3' GAPDH-F: 5'-TGGGGTGG-TGAATACCATGT-3'; GAPDH-R; 5'-AAGGCATGGCTG-CAACTGAA-3'; FGFR2-F2: 5'-GCCGCT-GTTTAGACG-TAATG-3'; FGFR2-R2: 5'-TCTCCCAAAGCACCAAGT-CT-3'; PSA-F: 5'-AGGCTGGGGCAGCATTGAAC-3'; PSA-R: 5'-CACCTTCTGAGGGTGAACTTG-3' PCR was performed with 50 ng of genomic DNA and the number of cycles was selected so as to be in the exponential part of the two PCR reactions (i.e. 23 cycles). PCR products were analysed as described in the reverse transcription-PCR section.
Sequencing of the 5' region of the FGFR2 gene and methylation analysis
Screening of a human PAC genomic library led to the isolation of a clone containing the 5' region of the FGFR2 gene. Two kb of this clone were sequenced and the putative promoter region was identi®ed by comparison with the promoter sequence of the mouse gene (Avivi et al., 1992) . A quantitative PCR assay, adapted from that of Singer-Sam et al. (1990) , based on the inability of certain restriction enzymes to cut methylated DNA, was used to assess the methylation status of the CpG island of the 5' region of the FGFR2 gene. DNA (1 mg) from each tissue sample or cell line was cut with ten units of A¯II and ten units of MspI (methylation-insensitive) or SacII, CfoI, EagI, SmaI or HpaII (all ®ve methylation-sensitive) for 16 h at 378C (258C for SmaI). Restriction enzymes were then heat-inactivated. Digested DNA (50 ng) was ampli®ed with primers corresponding to sequences¯anking region 1 from the putative promoter of the FGFR2 gene (F-5'-AGTCACTCAGC-GAGCCGTTGG-3' and R-5'-GGGTCACGCCCCCACT-GAAAC-3') or¯anking region 2, from exon 1 (F-5'-CGAGCAAAGTTTGGTGGAGG-3' and R-5'-AGCA-ACTCCAAACGCAGAAGAGT-3') ( Figure 6 ). The reagents were as described above, except that 5% glycerol and 5% DMSO were added to facilitate amplification of the GC-rich fragment. The linear range of this PCRassay was determined by plotting cycle curves and 23 cycles were performed for the quantitative analyses. There was a negative control for ampli®cation in each independent experiment, with the template DNA omitted from the PCR reaction.
SSCP analysis cDNA, obtained as described above (see`Reverse transcription-PCR analysis' section) was ampli®ed by PCR using a set of 15 overlapping primer pairs covering the entire coding region of FGFR2-IIIb. Thirty-®ve cycles of radioactive PCR were performed using 10 ng of reverse-transcribed RNA in the presence of [a 33 P]dCTP. The PCR products were analysed as described elsewhere (Ahomadegbe et al., 1995) . Aberrantly migrating bands were excised and reampli®ed with the same set of primers. The PCR products were sequenced on both strands, using a cycle-sequencing kit (Pharmacia). The sequencing primers used were the same as those used for PCR ± SSCP. Abbreviations FGFR2-IIIb, ®broblast growth factor receptor 2-IIIb; PCR, polymerase chain reaction
